All Articles

A new collaboration aims to bolster pharmaceutical ingredient security through advanced biosynthesis and fermentation, addressing critical vulnerabilities in global drug supply chains.

A new program aims to tackle soaring health costs by offering employer-sponsored access to popular weight-loss drugs, potentially expanding access while curbing expenses.

Bracco Imaging’s AI-powered brain scan enhancement, AiMIFY™, receives regulatory approval in Brazil, signaling a growing trend of AI integration in medical imaging and opening doors to a key emerging market.

Canadian luxury outerwear brand SENTALER opens its first US boutique on Madison Avenue, signaling a commitment to experiential retail and sustainable practices. The move aligns with growing demand for ethical luxury and immersive brand experiences.

The Health Research Foundation recognizes Dr. Jeffrey Weitz and Dr. Juliet Daniel for groundbreaking contributions to medical science and a commitment to inclusivity in health research, addressing critical gaps in patient care.

From millions of lights to a sub-zero ice sculpture exhibit, Gaylord Hotels is doubling down on creating unforgettable holiday destinations. But can the scale of these experiences justify the cost – and the environmental impact?

New resources aim to empower patients with advanced prostate cancer to understand and access vital genetic testing, potentially unlocking personalized treatment options. But systemic hurdles remain.

Octopus AIM VCT 2 plc has completed a share buyback, reducing its issued share capital. Analysts examine the move's implications for investors and the broader VCT landscape, assessing financial health & future prospects.

Amid ongoing drug shortages, Phlow Corp. is advocating for a stronger domestic pharmaceutical supply chain. CEO Dr. Eric Edwards testified before Congress, highlighting the need for resilience and innovation in American medicine.

New report reveals 97% of organizations impacted by supply chain breaches, despite increased investment in security. Is the focus on compliance eclipsing genuine risk reduction?

A preliminary valuation of Oncotelic Therapeutics’ joint venture pipeline has reached $1.7 billion, spotlighting the potential of targeted nanomedicine and the growing appetite for innovative biotech assets in Hong Kong.

As electric vehicles and energy storage surge, a new fire suppression technology is being evaluated in Honolulu. Will this water-based agent prove effective against increasingly dangerous battery fires?

The convenient nutrition company authorizes a $600M share repurchase program, signaling confidence despite lowered growth forecasts and increased competition. A deeper look at the strategy and what it means for investors.

A strategic alliance aims to restore investor confidence in Panama's citizenship-by-investment program, boosting tourism and real estate development in the Central American nation.

Minovia Therapeutics is set to present encouraging clinical and pre-clinical data for its mitochondrial augmentation technology at ASH. The company is also pursuing a listing on Nasdaq through a merger with LaunchOne Acquisition Corp, potentially unlocking a new era of treatment for Myelodysplastic Syndromes.

As enterprises increasingly adopt decentralized technologies, a critical security gap emerges. Checkmarx and CredShields are joining forces to offer a comprehensive AppSec solution for the rapidly evolving Web3 landscape.

Texas-based Cipher Mining secures $333M to expand its data center footprint, betting on HPC demand despite cryptocurrency market uncertainties. A deep dive into the company's strategy and its impact on the infrastructure landscape.

The acquisition signals a growing trend toward AI-enhanced internal platforms, with uStudio poised to deliver intelligent audio and video experiences for a more engaged workforce.

The energy conversion and control systems leader is boosting its share repurchase program to $1.8 billion, underscoring strong financial health and a commitment to delivering value to shareholders amid a dynamic market.

ENDRA Life Sciences’ thermoacoustic imaging technology aims to disrupt the liver disease diagnostics market with a cost-effective, accessible alternative to MRI. But can this financially challenged medtech firm deliver on its promise?